A spectrophotometric method for the assay of lamivudine in pure form and in dosage form was developed in this study. The method was based on charge-transfer complex formation between the drug, which acted as n-donor w...A spectrophotometric method for the assay of lamivudine in pure form and in dosage form was developed in this study. The method was based on charge-transfer complex formation between the drug, which acted as n-donor while chloranilic acid and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) acted as a p-acceptor in a non-aqueous solvent in each case. Chloranilic acid was found to form a charge-transfer complex in a 1:1 stoichiometry with lamuvudine (lamivudine-chloranilic acid) with a maximium absorption band at 521 nm. Also, DDQ was found to form a charge-transfer complex in a 1:1 stoichiometry with lamivudine (lamivudine-DDQ) with a maximium absorption band at 530 nm. The pH was obeyed at acid range. The complexes obeyed Beer’s law at a concentration range of 0.04 - 0.28 mg/ml. The thermodynamic parameters calculated at different temperatures included the molar absorptivity, association constant, free energy change, enthalpy and entropy. The proposed method has been conveniently applied in the analysis of commercially available lamivudine tablet with good accuracy and precision.展开更多
A sensitive spectrofluorimetric method was developed for determination of ciprofloxacin (CPFX), levofloxacin (LEV), gatifloxacin (GAT) and moxifloxacin (MOX) in pure, commercial formulations, human urine and plasma. T...A sensitive spectrofluorimetric method was developed for determination of ciprofloxacin (CPFX), levofloxacin (LEV), gatifloxacin (GAT) and moxifloxacin (MOX) in pure, commercial formulations, human urine and plasma. The method is based on charge-transfer (CT) complex with chloranilic acid. Fluorescence intensity of the complexes was measured at emission wavelength ranging from 445-492 nm with excitation wavelengths from 285-330 nm. At optimum experimental conditions, a linear calibration plot was obtained in the concentration range of 20-1000 ng·mL-1, 60-320 ng·mL-1, 20-800 ng·mL-1 and 20 -00 ng·mL-1 for CPFX, LEV, MOX and GAT, respectively with good correlation coefficient in the range of 0.9929-1.0 in methanolic medium. The limit of detection and limit of quantification were found to be 5 ng·mL-1 and 18 ng·mL-1 for CPFX, 12 ng·mL-1 and 40 ng·mL-1 for LEV, 8 ng·mL-1 and 19 ng·mL-1 for MOX, 6 ng·mL-1 and 19 ng·mL-1 for GAT, respectively. The method was found free of interferences from excipients used as additive in pharmaceutical preparations, some common cations and compounds present in urine and plasma as well as co-administered analgesic, vitamins and other drugs. The method was successfully applied for quantification of selected fluoroquinolones in commercial formulations and also in spiked human urine and plasma samples with percent recoveries of 100.0 ± 1.56 and 100.2 ± 1.29 respectively.展开更多
文摘A spectrophotometric method for the assay of lamivudine in pure form and in dosage form was developed in this study. The method was based on charge-transfer complex formation between the drug, which acted as n-donor while chloranilic acid and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) acted as a p-acceptor in a non-aqueous solvent in each case. Chloranilic acid was found to form a charge-transfer complex in a 1:1 stoichiometry with lamuvudine (lamivudine-chloranilic acid) with a maximium absorption band at 521 nm. Also, DDQ was found to form a charge-transfer complex in a 1:1 stoichiometry with lamivudine (lamivudine-DDQ) with a maximium absorption band at 530 nm. The pH was obeyed at acid range. The complexes obeyed Beer’s law at a concentration range of 0.04 - 0.28 mg/ml. The thermodynamic parameters calculated at different temperatures included the molar absorptivity, association constant, free energy change, enthalpy and entropy. The proposed method has been conveniently applied in the analysis of commercially available lamivudine tablet with good accuracy and precision.
文摘A sensitive spectrofluorimetric method was developed for determination of ciprofloxacin (CPFX), levofloxacin (LEV), gatifloxacin (GAT) and moxifloxacin (MOX) in pure, commercial formulations, human urine and plasma. The method is based on charge-transfer (CT) complex with chloranilic acid. Fluorescence intensity of the complexes was measured at emission wavelength ranging from 445-492 nm with excitation wavelengths from 285-330 nm. At optimum experimental conditions, a linear calibration plot was obtained in the concentration range of 20-1000 ng·mL-1, 60-320 ng·mL-1, 20-800 ng·mL-1 and 20 -00 ng·mL-1 for CPFX, LEV, MOX and GAT, respectively with good correlation coefficient in the range of 0.9929-1.0 in methanolic medium. The limit of detection and limit of quantification were found to be 5 ng·mL-1 and 18 ng·mL-1 for CPFX, 12 ng·mL-1 and 40 ng·mL-1 for LEV, 8 ng·mL-1 and 19 ng·mL-1 for MOX, 6 ng·mL-1 and 19 ng·mL-1 for GAT, respectively. The method was found free of interferences from excipients used as additive in pharmaceutical preparations, some common cations and compounds present in urine and plasma as well as co-administered analgesic, vitamins and other drugs. The method was successfully applied for quantification of selected fluoroquinolones in commercial formulations and also in spiked human urine and plasma samples with percent recoveries of 100.0 ± 1.56 and 100.2 ± 1.29 respectively.
